Dr. Imran I. Ali, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 37
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 299
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
OH license 35070677 -
Clinical Neurophysiology Physician
OH license 35.070677 -
Epilepsy Physician
OH license 35.070677
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Promedica Toledo Hospital Toledo, OH
- Bay PArk Community Hospital Oregon, OH
- Promedica Monroe Regional Hospital Monroe, MI
- Promedica Charles and Virginia Hickman Hospital Adrian, MI
- Memorial Hospital Fremont, OH
Medical groups
- University of Toledo Physicians LLC (403 clinicians)
- Promedica Multi Specialty Physicians (270 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 299
- Services billed
- 2,943
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 131 | 95 |
| Measurement of brain wave activity (eeg), awake and drowsy | 110 | 108 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 103 | 64 |
| Established patient office or other outpatient visit, 20-29 minutes | 73 | 70 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 58 | 51 |
| Measurement of brain wave activity (eeg), awake and asleep | 44 | 44 |
| Measurement of brain wave activity (eeg), in coma or asleep | 32 | 31 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 31 | 21 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 25 | 18 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 24 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Lamotrigine Other prescribers in Toledo, OH | 621 |
| Levetiracetam Other prescribers in Toledo, OH | 517 |
| Lacosamide Other prescribers in Toledo, OH | 485 |
| Clobazam | 317 |
| Topiramate Other prescribers in Toledo, OH | 218 |
| Xcopri (cenobamate) | 177 |
| Carbamazepine Er (carbamazepine) Other prescribers in Toledo, OH | 130 |
| Divalproex Sodium Other prescribers in Toledo, OH | 103 |
| Oxcarbazepine Other prescribers in Toledo, OH | 102 |
| Lamictal (lamotrigine) Other prescribers in Toledo, OH | 100 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 6 payments worth $97.61 in total to this clinician.
| Pfizer Inc. | $63.19 |
|---|---|
| Amgen Inc. | $34.42 |
| Food and Beverage | $97.61 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $52,716 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)
Alnylam Pharmaceuticals Inc. - A study of soticlestat as an add-on therapy in children and adults with dravet syndrome or lennox-gastaut syndrome
Takeda Pharmaceuticals U.S.A., Inc. - Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
Alnylam Pharmaceuticals Inc. - An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. · Terminated · NCT04686786 - A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. · Completed · NCT04244175
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.